Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48-72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy.

[Educated donor--safe patient].

Unlabelled: The safety of transfusion is still improving and very important is raising of education among donors. The important element is also awareness of the possibility of withdrawing themselves from the donation process when they know that their blood isn't suitable for recipients.

Aim: The aim of this study was checked of donor's knowledge about the risk of transfusion transmitted infections.

[Iron stores in regular blood donors].

The aim of this study was to assess the iron balance status in the group of 151 male regular blood donors with normal hemoglobin (Hb) and hematocrit (Ht) level who had given over 10 donations of the whole blood with the frequency of 4-6 units per year. We though to determine the prevalence of iron deficiency in this group of donors and its relationship with the cumulative number of previously given blood, as well as to compare the sensitivity of serum ferritin (FRT) with serum soluble transferrin receptor (sTfR) level in detecting tissular iron stores depletion in donors with normal blood count. The control group comprised 50 age-matched first-time donors.